PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • Veteran Johnson & Johnson Executive Dr. Ajit Shetty Joins PreveCeutical

    Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is very pleased to announce the appointment of Dr. Ajit Shetty as an advisor and consultant for the Company.Dr. Shetty brings his extensive pharmaceutical experience leading commercial and supply chain operations and his significant educational background to the Company. Dr. Shetty spent 36 years at Johnson & Johnson ("J&J") in a wide range of global roles. From...

    2020-10-01 10:36 AM ET
  • PreveCeutical Provides Lead Pain Management Peptides Update

    Vancouver, British Columbia--(Newsfile Corp. - September 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update to its non-addictive analgesic program ("Analgesic Program").Further to the news release of September 2, 2020, the Analgesic Program consisted of an iterative approach to peptide design resulting in a number of second-generation peptide analogues optimized from the most promising first-generation series. Cell and stability testing results correlate well with the pilot animal studies....

    2020-09-08 6:00 AM ET
  • PreveCeutical Announces Lead Pain Management Peptides Identified for Preclinical Evaluation

    Vancouver, British Columbia--(Newsfile Corp. - September 2, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update to its non-addictive analgesic program ("Analgesic Program").The Analgesic Program started in July 2018 to discover and develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation. This discovery program, which utilizes a proprietary disulfide linker technology, is in its final steps of completion. Several promising lead peptides have been identified, which...

    2020-09-02 6:00 AM ET
  • PreveCeutical Files an Application for a Provisional Patent for Sol-gel Cannabinoids

    Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on August 31, 2020, entitled "Cannabinoid Formulations and Methods of Use", application number 2020903103, in order to protect sol-gel formulations containing cannabinoids for nasal delivery.The patent also covers cannabinoid formulations with respect to sativa, indica, hybrid combination, and hemp plants. The patent also refers...

    2020-08-31 6:00 AM ET
  • PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund

    Vancouver, British Columbia--(Newsfile Corp. - August 17, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received AU$1,227,902 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2019. The R&D activities were across PreveCeutival's portfolio, including the Sol-gel nose-to-brain drug delivery system and the...

    2020-08-17 6:00 AM ET
  • PreveCeutical Announces Appointment of Director and Public Officer

    Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointment of Edward James Henderson as the Public Officer and Director of its subsidiary company, PreveCeutical (Australia) Pty Ltd. (the "Subsidiary") effective immediately.Mr. Henderson is HLB Mann Judd's Managing Partner, Business Advisory Services, Tax Consulting, Brisbane, Queensland, Australia. Mr. Henderson is a respected business strategist with an extensive range of expertise and...

    2020-07-30 6:00 AM ET
  • PreveCeutical Approaches Completion of Non-Addictive Analgesic Program

    Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program ("Analgesic Program") is soon to complete. The results are currently being compiled and analyzed.The Analgesic Program started in July 2018 to expand the use of the University of Queensland's disulfide linker technology to develop...

    2020-07-21 6:00 AM ET
  • PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

    Vancouver, British Columbia--(Newsfile Corp. - July 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program.This update of PreveCeutical's Dual Gene Therapy Program, (see earlier release on January 14, 2020, and June 29, 2020), has identified a promising modified delivery vector ready for possible pre-clinical experiments. It is based...

    2020-07-15 6:00 AM ET